Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In all but one of the patient cases, calcium and vitamin D supplementation were either reduced or discontinued completely after a formal diagnosis and a lower serum calcium level (depending on patient tolerance and symptoms) was accepted as a physiological baseline.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case series.

Case series

Describes a group of individual cases.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England

Source: Article title.

Patients were consented to a national rare disease registry (RaDaR) () ().

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England

Case series · Journal of the Endocrine Society · 2026

Original publication title

Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England

Deepika Manoharan; Edwin K S Wong; Holly Mabillard; Shalabh Srivastava; Simon H S Pearce; John A Sayer

© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

ADH1 is a multisystem disorder with substantial morbidity, including nephrocalcinosis, CKD, and a risk of KF despite cautious management. Other significant features include hypocalcemic seizures and intracranial calcification. These findings emphasize the necessity of early genetic diagnosis, family screening, and longitudinal renal surveillance. The high complication burden under conventional therapy underscores the need for targeted treatments, such as CaSR antagonists (calcilytics), to improve long-term outcomes.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To describe a case series of adults with genetically confirmed AHD1.

Source: Objective

Abstract: What methods does the paper describe?

We reviewed 9 adults with genetically confirmed ADH1 in North East England (2005-2024). Clinical, biochemical, and imaging data were retrospectively analyzed from electronic records. Pathogenic CASR variants were identified via accredited genomic panels.

Source: Methods

Abstract: Context

Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder caused by activating CASR variants, characterized by hypocalcemia, low/normal parathyroid hormone, and hypercalciuria. While managed with conservative calcium targets to prevent renal damage, the long-term systemic burden remains poorly defined.

Source: Context

Abstract: Results

The cohort (n = 9; 5 female; age 24-57) was 89% familial, with all exhibiting persistent hypocalcemia and 66% presenting with hypomagnesemia. Renal involvement affected 78%, including nephrocalcinosis (56%), nephrolithiasis (67%), and chronic kidney disease (CKD), with 2 patients from 1 kindred progressing to kidney failure (KF) and death. Extrarenal features included seizures, intracranial calcifications, dental abnormalities, and neuropsychiatric symptoms, often persisting despite conservative strategies to limit calcium supplementation post diagnosis. No clear correlation was found between mean serum calcium levels and disease severity, highlighting substantial phenotypic variability.

Source: Results

Abstract: Conclusion

ADH1 is a multisystem disorder with substantial morbidity, including nephrocalcinosis, CKD, and a risk of KF despite cautious management. Other significant features include hypocalcemic seizures and intracranial calcification. These findings emphasize the necessity of early genetic diagnosis, family screening, and longitudinal renal surveillance. The high complication burden under conventional therapy underscores the need for targeted treatments, such as CaSR antagonists (calcilytics), to improve long-term outcomes.

Source: Conclusion
Authors’ abstract

Abstract

Context

Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder caused by activating CASR variants, characterized by hypocalcemia, low/normal parathyroid hormone, and hypercalciuria. While managed with conservative calcium targets to prevent renal damage, the long-term systemic burden remains poorly defined.

Objective

To describe a case series of adults with genetically confirmed AHD1.

Methods

We reviewed 9 adults with genetically confirmed ADH1 in North East England (2005-2024). Clinical, biochemical, and imaging data were retrospectively analyzed from electronic records. Pathogenic CASR variants were identified via accredited genomic panels.

Results

The cohort (n = 9; 5 female; age 24-57) was 89% familial, with all exhibiting persistent hypocalcemia and 66% presenting with hypomagnesemia. Renal involvement affected 78%, including nephrocalcinosis (56%), nephrolithiasis (67%), and chronic kidney disease (CKD), with 2 patients from 1 kindred progressing to kidney failure (KF) and death. Extrarenal features included seizures, intracranial calcifications, dental abnormalities, and neuropsychiatric symptoms, often persisting despite conservative strategies to limit calcium supplementation post diagnosis. No clear correlation was found between mean serum calcium levels and disease severity, highlighting substantial phenotypic variability.

Conclusion

ADH1 is a multisystem disorder with substantial morbidity, including nephrocalcinosis, CKD, and a risk of KF despite cautious management. Other significant features include hypocalcemic seizures and intracranial calcification. These findings emphasize the necessity of early genetic diagnosis, family screening, and longitudinal renal surveillance. The high complication burden under conventional therapy underscores the need for targeted treatments, such as CaSR antagonists (calcilytics), to improve long-term outcomes.

Publication and source details

Original title: Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England

Deepika Manoharan; Edwin K S Wong; Holly Mabillard; Shalabh Srivastava; Simon H S Pearce; John A Sayer

Journal of the Endocrine Society · 2026

Correspondence: John A. Sayer, MB ChB, PhD, Faculty of Medical Sciences, Biosciences Institute, Newcastle University, Central Parkway, Newcastle Upon Tyne, Tyne and Wear, NE1 3BZ, UK. Email: John.sayer@newcastle.ac.uk.© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. MRC10.13039/501100020643 MR/V028723/1MR/Y007808/1MR/V005898/1 LifeArc10.13039/100012357 Kidney Research UK10.13039/501100000291 RP_007_20210729 Northern Counties Kidney Research Fund10.13039/501100004185 20/01

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:45:34.070962+00:00

DOI: 10.1210/jendso/bvag205 · PMC13595229